← Back to Patent Explorer
US4554284A Expired / Lapsed US ⏱️ 0.0 years remaining

7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones

Assignee: SmithKline Beecham Corp
•
Filing: 1984-09-12
•
Granted: 1985-11-19
•
Expires: 2004-09-12
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Certain aminoethyl substituted 1,3-benzthiazol- and 1,3-benzoxazol-2(3H)-ones are D 2 -dopamine agonists. These compounds are prepared by reacting an appropriate o-aminophenol or thiophenol with phosgene.

Inventors

  • 👤 Orum D. Stringer
  • 👤 Joseph Weinstock

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 14:29
CPC Classifications
C; C07; C07D; C07D263/00; C07D263/52; C07D263/54; C07D263/58; A; A61; A61P; A61P9/00; A61P9/08; A61P9/10; A61P9/12; C07D277/00; C07D277/60; C07D277/62; C07D277/68

Claims Analysis

Total Claims: 15
Claim 1
Independent Claim 62 words
A chemical compound of the formula: ##STR4## in which: X is --S--or --O--; R 1 and R 2 are, each, hydrogen, C 1-6 -alkyl, allyl, benzyl, phenethyl, methoxyphenethyl or hydroxyphenethyl; and R 3 and R 4 are, each, hydroxy, hydrogen, halo, C 1-3 -alkyl or C 1-3 -alkoxy, a pharmaceutically acceptable, acid addition salt thereof or an O-C 2-6 -alkanoyl derivative thereof.
Claim 2
Dependent Claim 62 words
A chemical compound of the formula: ##STR4## in which: X is --S--or --O--; R 1 and R 2 are, each, hydrogen, C 1-6 -alkyl, allyl, benzyl, phenethyl, methoxyphenethyl or hydroxyphenethyl; and R 3 and R 4 are, each, hydroxy, hydrogen, halo, C 1-3 -alkyl or C 1-3 -alkoxy, a pharmaceutically acceptable, acid addition salt thereof or an O-C 2-6 -alkanoyl derivative thereof.
Claim 3
Dependent Claim 15 words
The compound of claim 1 in which R 1 and R 2 are both n-propyl.
Claim 4
Dependent Claim 10 words
The compound of claim 1 in which X is --S--.
Claim 5
Dependent Claim 21 words
The compound of claim 1 in which X is --S--, R 3 is hydrogen and R 4 is 4-hydroxy or hydrogen.
Claim 6
Dependent Claim 15 words
The compound of claim 1 being 4-hydroxy-7-[2-(di-n-propylamino)ethyl]-1,3-benzthiazol-2(3H)-one or a pharmaceutically acceptable, acid addition salt thereof.
Claim 7
Dependent Claim 8 words
The compound of claim 1 being 4-hydroxy-7-[2-(di-n-propylamino)ethyl]-1,3-benzthiazol-2(3H)-one hydrobromide.
Claim 8
Dependent Claim 15 words
The compound of claim 1 being 4-hydroxy-7-[2-(di-n-propylamino)ethyl-1,3-benzoxazol-2(3H)-one or a pharmaceutically acceptable, acid addition salt thereof.
Claim 9
Dependent Claim 15 words
The compound of claim 1 being 7-[2-(di-n-propylamino)ethyl]-1,3-benzthiazol-2(3H)-one or a pharmaceutically acceptable, acid addition salt thereof.
Claim 10
Dependent Claim 15 words
The compound of claim 1 being 7-[2-(n-propylamino)ethyl]-1,3-benzthiazol-2(3H)-one or a pharmaceutically acceptable, acid addition salt thereof.
Claim 11
Dependent Claim 26 words
A pharmaceutical composition having D 2 -agonistic activity comprising an effective therefor but nontoxic quantity of a compound of claim 1 combined with a pharmaceutical carrier.
Claim 12
Dependent Claim 20 words
The composition of claim 10 in which the composition is for oral administration and is effective for treatment of hypertension.
Claim 13
Dependent Claim 30 words
The composition of claim 10 in which the compound is 4-hydroxy-7-[2-(di-n-propylamino)ethyl]-1,3-benzthiazol-2(3H)-one or a pharmaceutically acceptable, acid addition salt thereof and the D 2 -agonistic activity is manifested in anti-hypertensive activity.
Claim 14
Dependent Claim 32 words
The method of inducing D 2 -agonistic activity in a patient in need thereof comprising administering internally to said patient a D 2 -agonistic, nontoxic quantity of a compound of claim 1.
Claim 15
Dependent Claim 16 words
The method of claim 13 in which the patient is hypertensive and the administration is oral.

References Cited (Backward Citations)

US4474965A Cited
US4314944A Cited
FR2491471A1 Cited
US4460581A Cited
US4452808A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1988-11-18 1989-05-20 1989-11-19 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1992-11-18 1993-05-20 1993-11-19 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1996-11-18 1997-05-20 1997-11-19 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag